P.038 Clinical experience with perampanel for refractory pediatric epilepsy in one Canadian center
نویسندگان
چکیده
منابع مشابه
Perampanel for focal epilepsy: insights from early clinical experience
Perampanel is approved for adjunctive therapy of focal epilepsy with or without secondarily generalized seizures in patients aged >12 years. This narrative review uses real-world and clinical trial data to elucidate perampanel's role in the clinic. Audit data show good tolerability with perampanel and higher freedom-from-seizure rates in elderly vs younger patients. When using perampanel in eld...
متن کاملCurrent role of perampanel in pediatric epilepsy
Perampanel is among the latest AEDs approved, indicated for the treatment of partial-onset seizures with or without secondary generalization, and for primary generalized tonic-clonic seizures, in patients aged 12 years and older. This paper summarizes the clinical recommendations on the current role of perampanel in the treatment of pediatric epilepsies and future directions for research. The o...
متن کاملTreating refractory epilepsy with tiagabine: clinical experience
Epilepsy remains difficult to treat with more than 30% of patients being refractory to conventional anticonvulsant therapy. Combination therapy may improve seizure control in some of these patients. Tiagabine is a new anticonvulsant that has a unique mechanism of action as a selective gamma-aminobutyric acid (GABA) re-uptake inhibitor (SGRI). Twenty consecutive patients with refractory epilepsy...
متن کاملClinical Characteristics of Pediatric Esophagitis in Southern Iran; A Single-Center Experience
Background: We sought to determine the clinical characteristics of pediatric esophagitis in southern Iran. Methods: This cross-sectional study was conducted over a 4-year period, from 2005 to 2009, in Nemazee Hospital, a tertiary healthcare center in Shiraz, southern Iran. We consecutively included all pediatric patients (< 18 years) who underwent endoscopy in our center and had pathology...
متن کاملAdjunctive perampanel for refractory partial-onset seizures
Methods: This was a multicenter, double-blind, placebo-controlled trial (ClinicalTrials.gov identifier: NCT00699972). Patients ( 12 years, with ongoing seizures despite 1–3 AEDs) were randomized (1:1:1) to once-daily perampanel 8 mg, 12 mg, or placebo. Following baseline (6 weeks), patients entered a 19-week double-blind phase: 6-week titration (2 mg/week increments to target dose) followed by ...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques
سال: 2017
ISSN: 0317-1671,2057-0155
DOI: 10.1017/cjn.2017.123